Sarah Gheuens

Sarah Gheuens

Chief Medical Officer, Head of Research & DevelopmentatAgios Pharmaceuticals· In proxies 2021–2025

Pay in FY2025-18% from the year before · Agios Pharmaceuticals stock -17.2% the same year

Sarah Gheuens was paid $2.1M in FY2025 (Dec), down 18%. Agios Pharmaceuticals stock fell 17.2% that year.

Pay$100 in the stock at the end of FY20 → $63
Pay is from the Summary Compensation Table of each Agios Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Agios PharmaceuticalsPublic company · 5 yr
    • Chief Medical Officer, Head of Research & Development2021 – Present · 5 yrStock in role -16%
  2. Viridian Therapeutics, Inc.\DEPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Viridian Therapeutics, Inc.\DEDirector · 0 yr on the boardIndependentScience—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?